RecruitingNCT05461664

Avapritinib in the Treatment of Unresectable or Recurrent Metastatic GIST Non-exon18 Mutations of PDGFRA

Avapritinib in the Treatment of Unresectable or Recurrent Metastatic Gastrointestinal Stromal Tumors Non-exon18 Mutations of PDGFRA:A Real-world Study

Sponsor

Xinhua Zhang, MD

Enrollment

74 participants

Start Date

Jul 10, 2022

Study Type

OBSERVATIONAL

Conditions

Unresectable Solid Tumor Gastrointestinal Stromal Tumors Recurrent Metastatic Malignant Neoplasm

Summary

This is a prospective, multicenter, observational real-world study to explore the Avapritinib therapy in GIST patients who definited Non-exon18 Mutations of PDGFRA.

Eligibility

Min Age: 18 Years

Plain Language Summary

Simplified for easier understanding

This clinical trial is studying a new treatment for people with gastrointestinal stromal tumors, recurrent metastatic malignant neoplasm, and other related conditions. The study is currently recruiting participants at 1 location. People eligible for this study include aged 18 Years and older.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.